Repository logo
 

$\textit{XACT}$ Noncoding RNA Competes with $\textit{XIST}$ in the Control of X Chromosome Activity during Human Early Development

Published version
Peer-reviewed

Change log

Authors

Vallot, C 
Patrat, C 
Collier, AJ 
Huret, C 
Casanova, M 

Abstract

Sex chromosome dosage compensation is essential in most metazoans, but the developmental timing and underlying mechanisms vary significantly, even among placental mammals. Here we identify human-specific mechanisms regulating X chromosome activity in early embryonic development. Single-cell RNA sequencing and imaging revealed co-activation and accumulation of the long noncoding RNAs (lncRNAs) XACT and XIST on active X chromosomes in both early human pre-implantation embryos and naive human embryonic stem cells. In these contexts, the XIST RNA adopts an unusual, highly dispersed organization, which may explain why it does not trigger X chromosome inactivation at this stage. Functional studies in transgenic mouse cells show that XACT influences XIST accumulation in cis. Our findings therefore suggest a mechanism involving antagonistic activity of XIST and XACT in controlling X chromosome activity in early human embryos, and they highlight the contribution of rapidly evolving lncRNAs to species-specific developmental mechanisms.

Description

Keywords

XACT, XIST, dosage compensation, human X chromosome inactivation, long noncoding RNA, naive pluripotency, preimplantation development

Journal Title

Cell Stem Cell

Conference Name

Journal ISSN

1934-5909
1875-9777

Volume Title

20

Publisher

Elsevier
Sponsorship
European Commission (257082)
Medical Research Council (MC_PC_12009)
The research leading to these results has received funding from the European Research Council under the EpiGeneSys FP7 257082 Network of Excellence (to C.R., E.H., and P.J.R.-G.), from the Agence Nationale pour la Recherche (ANR-11-LABX-0071, to C.R. and E.H.), from the Ligue Nationale contre le Cancer (to C.R.), and from the DIM Biotherapies (to E.H. and C.P.). T.M.L.A. is supported by a fellowship from the INCa/INSERM Plan cancer (EPIG201414). P.J.R.-G. is supported by the Wellcome Trust (WT093736) and the Biotechnology and Biological Sciences Research Council (BBSRC) (BBS/E/B/000C0402).